Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fresenius expands venture with ML Laboratories (UK):

This article was originally published in Clinica

Executive Summary

Fresenius (Germany) and ML Laboratories (UK) have entered into a provisional agreement to expand their joint activities in peritoneal dialysis. The companies will set up two joint ventures: one in Germany, 20%-owned by ML, to target the continental European isodextrin-solution peritoneal dialysis market; and a second, 75%-owned by ML, in the UK. Fresenius will also obtain the exclusive US distribution rights for isodextrin solutions in the US. The two companies originally signed a joint deal in March 1993 (see Clinica No 593, p 13).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT092072

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel